News

Kalvista Pharmaceuticals’ sebetralstat, an oral on-demand treatment for hereditary angioedema (HAE), rapidly stopped the progression of swelling attacks, according to interim data from a two-year open-label extension study. It was also effective against attacks involving the larynx (voice box) and abdomen, as well as those rated as severe or…

Recognizing a problem early and treatment can help avoid life-threatening complications when swelling of the larynx, or voice box, caused by hereditary angioedema (HAE) blocks the airways. That’s according to a report that describes the case of a man in China with hereditary angioedema-induced laryngeal edema (HALE), which can…

The use of Orladeyo (berotralstat) — widely approved as a preventive treatment for hereditary angioedema (HAE) — can help reduce the rates of swelling attacks in people with HAE of different ages, according to new data from clinical trials and real-world analyses. Biocryst Pharmaceuticals, the developer of the…

A new scoring system may help emergency physicians diagnose hereditary angioedema (HAE), potentially allowing patients to receive treatment faster, a study found. Nine HAE experts worked together to design the system, which assigns patients numerical scores based on their symptoms, family history, and responsiveness to certain treatments. “This tool…

Treatment with the daily oral therapy Orladeyo (berotralstat) can effectively reduce swelling attack rates in people with hereditary angioedema (HAE) who experienced many such attacks before starting on the therapy, real-world data showed. Additional real-world data indicated that Orladeyo is also effective for preventing swelling attacks in adolescents…

Donidalorsen, a preventive therapy being developed to reduce the frequency of swelling attacks for people with hereditary angioedema (HAE), significantly improved quality of life and symptom control for people with the condition, a new analysis of clinical trial data suggests. Ionis Pharmaceuticals, donidalorsen’s developer, funded the study,…

The U.S. Food and Drug Administration (FDA) has accepted Biocryst Pharmaceuticals’ application to approve an oral granule formulation of Orladeyo (berotralstat) for children with hereditary angioedema (HAE) as young as 2. The FDA granted the application priority review, which shortens the process from the standard 10 months…

To mark Hereditary Angioedema (HAE) Awareness Day this year, the advocacy group HAE International is smiling: The theme for the events of Friday, May 16, is “hae day,” with punctuation marks creating a smiley face. An annual worldwide event, HAE Awareness Day aims to familiarize people with…

Biocryst Pharmaceuticals has submitted an application asking the U.S. Food and Drug Administration (FDA) to extend the approval of Orladeyo (berotralstat) to children with hereditary angioedema (HAE) as young as 2 years. The application specifically seeks the approval of an oral granule formulation of the therapy for…

The use of the antibody navenibart, being developed by Astria Therapeutics to prevent swelling episodes in hereditary angioedema (HAE), resulted in the sustained inhibition of kallikrein — an enzyme that’s overactive in HAE patients — in healthy volunteers in a clinical trial, supporting its…